Is CytoDyn Inc. (CYDY) a Buy, Sell, or Hold?
OTC : CYDY
CytoDyn Inc. — News
$0.2099 USD
$0.0 (-1.92%)
- Volume
- 507.61K
- Average Volume
- 1.93M
- Market Capitalization
- $287.51M
- P/E Ratio
- -6.56
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.40
- Year Low
- $0.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$0.03
- Current Ratio
- $0.37
| Source | Headline |
|---|---|
|
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
TACOMA, Wash., July 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP announces proposed class action settlement on behalf of purchasers of CytoDyn Inc. common stock between March 27, 2020 and March 30, 2022 (OTCQB: CYDY): UNITED STATES DISTRICT COURTWESTERN DISTRICT OF WASHINGTON AT TACOMA BRIAN JOE COURTER, COURTER AND SONS LLC, DIANE M. prnewswire.com - 2026-07-22 08:00:00 |
|
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple therapeutic indications, today announced that the first patient has been dosed in a Phase 2a clinical study evaluating leronlimab in patients with Alzheimer's disease, in collaboration with Weill Cornell Medicine. The study, known as SALIENT-AD (Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease), is a Phase 2a, open-label, proof-of-concept study designed to evaluate the safety and biological activity of leronlimab in approximately 10 to 20 patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease. globenewswire.com - 2026-06-11 08:30:00 |
|
CytoDyn to Present at the LD Micro Invitational XVI
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. globenewswire.com - 2026-05-15 08:30:00 |
|
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript seekingalpha.com - 2026-05-01 05:41:47 |
|
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development globenewswire.com - 2026-04-27 08:30:00 |
